Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
== Organization == The Brigade's origins trace back to July 1941, when a "Fighter Battalion" (Destruction Battalion) led by I.T Gustev was established in the Mekhovsky District. By July 18th, this unit was reorganized into the Mekhovsky Partisan Detachment under the command of K.F Volkov. Following a winter of skirmishes and internal restructuring, the detachment was expanded to a brigade on May 7th, 1942, into the 2nd Belarusian Partisan Brigade. By January 1943, the brigade had grown to include 9 detachments. These were given honorary names of Soviet military and revolutionary figures, such as Suvorov, Chapayev , and Stalin.
=== Australia === From 1 July 2012 Chinese medicine practitioners must be registered under the national registration and accreditation scheme with the Chinese Medicine Board of Australia and meet the Board's Registration Standards, to practice in Australia.
In the late 6th century, following Justinian I's wars, seven mobile field armies called comitatenses, numbering around 150,000 troops, were deployed around the empire; they remained the finest armies in Europe. They were aided by twenty-five frontier garrisons of approximately 195,000 lower-quality limitanei troops. Additional troops included subsidised allied forces and imperial guard units like the Scholae Palatinae. Naval forces were limited: flotillas were based at key locations, while 30,000 oarsmen were assembled to row 500, mostly requisitioned, transports to support the Vandalic War in Africa in 533. The losses suffered in the 7th-century Arab conquests led to fundamental changes. The field armies were withdrawn into the core Anatolian territories and assigned to settle in specific districts, which became known as themata and eventually replaced the old provinces. The thematic armies, supported by the proceeds of their districts, came to resemble a provincial militia with a small professional core, aided by foreign mercenaries and imperial regiments at Constantinople. To defend against its new Muslim enemy, the navy was similarly reorganised into several provincialised fleets. It became the dominant power in the eastern Mediterranean, with dromons equipped with Greek fire proving crucial on several occasions. As the 8th-century empire stabilised, the thematic militias proved rebellious and only suitable for defensive operations.
Sources: en.wikipedia.org
== Clinical relevance == IGF-2 is sometimes produced in excess in islet cell tumors and non-islet hypoglycemic cell tumors, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. Loss of imprinting of IGF-2 is a common feature in tumors seen in Beckwith-Wiedemann syndrome. As IGF-2 promotes development of fetal pancreatic beta cells, it is believed to be related to some forms of diabetes mellitus. Preeclampsia induces a decrease in methylation level at IGF-2 demethylated region, and this might be among the mechanisms behind the association between intrauterine exposure to preeclampsia and high risk for metabolic diseases in the later life of the infants. In animals it has been shown that toxins such as PCB (polychlorinated biphenyls) affects IGF II expression.
Ranitidine, a medicine for peptic ulcers sold under the name of Zantac, was developed by Allen & Hanburys (then a part of Glaxo Group Research, now GSK), and patented in 1978 (US4128658A, Example 32). Originally, its crystals were all in Form 1, but the batch prepared on April 15, 1980 exhibited a new infrared spectrogram peak at 1045 cm−1, demonstrating that a new crystal had appeared, designated Form 2. Subsequent batches produced more and more Form 2 despite using the same procedure, until Form 1 completely disappeared. The group patented Form 2 in 1985 (US4521431A ) and 1987 (US4672133A). Though it is very difficult to crystallize Form 1 in the presence of seeds of Form 2, if the two forms are already crystallized, then they can coexist indefinitely when mixed together. Later research showed that the two forms consists of different conformers of ranitidine, making this a case of conformational polymorphism. Specifically, the nitroethenediamine moiety of the ranitidine cations is rotated in different directions in the two forms. Also, that moiety is more disordered in Form 2. As the 1978 patent was nearing its 1995 expiration, many generics companies attempted to develop generics using the procedure described in 1978 patent, but they all ended up with Form 2. Some generics companies (such as Novopharm) claimed that Glaxo never produced Form 1, and thus the 1978 patent inherently anticipated Form 2, thus invalidating the 1985 and 1987 patents (since double patenting is invalid).
Cardiac amyloidosis is a subcategory of amyloidosis where there is depositing of the protein amyloid in the heart muscle and sometimes other organs or structures. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart's atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function and heart failure. The overall decrease in cardiac function leads to a plethora of symptoms. This multisystem disease was often misdiagnosed, with a definitive diagnosis only during autopsy. Advancements of technologies have led to earlier and more accurate diagnosis. However diagnosis may still be delayed as the disease may remain asymptomatic for years as amyloid deposits in the heart and other organs or tissues. Diagnosis may be delayed further as the disease may be misdiagnosed or confused for other more common conditions that cause heart enlargement (such as hypertension or other forms of heart failure). Cardiac amyloidosis has multiple sub-types including light chain, hereditary transthyretin amyloidosis (due to genetic variants leading to misfolded transthyretin protein depositing in the heart and other tissues), and wild type transthyretin amyloidosis (where misfolded transthyretin builds up in heart muscle and other tissues, but with an absence of any mutations).
Sources: en.wikipedia.org
== Science and technology == Rational polynomial coefficient Reactive Plastic Curtain, a carbon-dioxide-absorbing device used in some rebreather breathing sets Regional Playback Control, a regional lockout technology for DVDs Remote procedure call, an inter-process communication technique in networked computing Open Network Computing Remote Procedure Call, IETF RPC, a.k.a. "Sun RPC" DCE/RPC, for Distributed Computing Environment by Open Software Foundation JSON-RPC, a "JSON encoded" variant XML-RPC, an "XML encoded" variant Resistive plate chamber, a simple type of particle detector used in experimental particle physics Reversed-phase chromatography, a chemistry technique Acorn Risc PC Rocket Pod Container, the interchangeable containers used to transport and launch missiles for use with the M270 Multiple Launch Rocket System Rotary phase converter, an electrical machine that converts power from one polyphase system (including frequency) to another, converting through rotary motion.
Glycosidic bonds of the form discussed above are known as O-glycosidic bonds, in reference to the glycosidic oxygen that links the glycoside to the aglycone or reducing end sugar. In analogy, one also considers S-glycosidic bonds (which form thioglycosides), where the oxygen of the glycosidic bond is replaced with a sulfur atom. In the same way, N-glycosidic bonds, have the glycosidic bond oxygen replaced with nitrogen. Substances containing N-glycosidic bonds are also known as glycosylamines. C-glycosyl bonds have the glycosidic oxygen replaced by a carbon; the term "C-glycoside" is considered a misnomer by IUPAC and is discouraged. All of these modified glycosidic bonds have different susceptibility to hydrolysis, and in the case of C-glycosyl structures, they are typically more resistant to hydrolysis.
== History == The safety and efficacy of efgartigimod alfa were evaluated in a 26-week clinical study of 167 participants with myasthenia gravis who were randomized to receive either efgartigimod alfa or placebo. It was a randomized, double-blind, placebo-controlled trial. The study showed that more participants with myasthenia gravis with antibodies responded to treatment during the first cycle of efgartigimod alfa (68%) compared to those who received placebo (30%) on a measure that assesses the impact of myasthenia gravis on daily function. More participants receiving efgartigimod alfa also demonstrated response on a measure of muscle weakness compared to placebo. The trial was conducted at 56 sites in 15 countries in Belgium, Canada, the Czech Republic, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, the Netherlands, Poland, the Russian Federation, Serbia, and the US. Efgartigimod alfa is also studied for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The clinical trial known as ADHERE, conducted by Argenx, involved the enrollment of 322 individuals diagnosed with CIDP. In the initial phase of the study, all subjects received weekly injections of Vyvgart. Following a period of 12 weeks, it was observed that 67% of the patients exhibited positive responses to Vyvgart, as evidenced by improvements in their muscle disability scores.
Semirational mutagenesis of a number of residues led to pH-sensitive mutants known as pHluorins, and later super-ecliptic pHluorins. By exploiting the rapid change in pH upon synaptic vesicle fusion, pHluorins tagged to synaptobrevin have been used to visualize synaptic activity in neurons. Redox sensitive GFP (roGFP) was engineered by introduction of cysteines into the beta barrel structure. The redox state of the cysteines determines the fluorescent properties of roGFP.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.